Category - Feature

Feature

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

Tonix Pharmaceuticals (NASDAQ:TNXP) is engaged in a number of ongoing and planned clinical trials with a rich pipeline of products, including a Phase 3 clinical trial to treat fibromyalgia, along with a Phase 2 clinical...

July 19, 2022

Feature

TC Biopharm developing gamma-delta T-cells therapies for oncology

TC BioPharm (NASDAQ:TCBP) is a global leader in developing platform allogeneic gamma-delta T-cell therapies for cancer indications, with human efficacy data in acute myeloid leukemia (AML) and plans to expand into other...

July 12, 2022

Feature

Aristea Therapeutics in four clinical trials in rare inflammatory diseases

Closely-held Aristea Therapeutics is pursuing four rare inflammatory diseases with its oral, once-daily, small molecule drug candidate, RIST4721: palmoplantar pustulosis, familial Mediterranean fever, Behcet’s disease...

July 5, 2022

Feature

Pharvaris providing patient choice in developing oral treatments for hereditary angioedema

Pharvaris (NASDAQ:PHVS), a trans-Atlantic company, is developing two oral products to treat and prevent attacks in all subtypes of hereditary angioedema (HAE), with on-demand and prophylactic therapies.

June 28, 2022

Feature

NeuroSense advancing potential paradigm shift in ALS therapy

NeuroSense Therapeutics (NASDAQ:NRSN) is developing a novel fixed dose combination of two FDA-approved drugs for a multi-targeted approach against the potential pathways responsible for ALS, or amyotrophic lateral...

June 21, 2022

Feature

QSAM Biosciences developing next-gen targeted radiopharmaceuticals for cancer

QSAM Biosciences (OTCQB:QSAM) began dosing bone cancer patients in a Phase 1 study in April 2022 with its next-generation radiopharmaceutical, CycloSam, which delivers the beta-emitting radioisotope, samarium-153, to...

June 14, 2022

Feature

Synlogic advancing novel biotherapeutics based on synthetic biology

Synlogic (NASDAQ:SYBX) is advancing a new class of biotherapeutics, known as Synthetic Biotics, targeting validated biology in rare metabolic and immunological diseases.

June 7, 2022

Feature

Iterion Therapeutics addressing multiple cancers with TBL1 inhibition

Closely-held Iterion Therapeutics is employing a unique strategy with its lead asset, tegavivint, which is designed to bind to TBL1 (transducin beta-like protein one) and inhibit nuclear beta-catenin signaling and...

May 31, 2022

Feature

MindMed driving therapeutic potential of psychedelics for brain health disorders

MindMed (NASDAQ:MNMD; NEO:MMED) is advancing a pipeline of psychedelic and next generation drug candidates to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology.

May 24, 2022

Feature

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

Closely-held Lanier Biotherapeutics is pioneering a first-in-class Type 2 and non- Type2 anti-inflammatory biologic, LNR 125, as a new candidate targeting treatments commonly associated with Type 2 inflammation like...

May 17, 2022

Category - Feature

Tonix has multiple shots on goal in CNS, immunology and infectious diseases

TC Biopharm developing gamma-delta T-cells therapies for oncology

Aristea Therapeutics in four clinical trials in rare inflammatory diseases

Pharvaris providing patient choice in developing oral treatments for hereditary angioedema

NeuroSense advancing potential paradigm shift in ALS therapy

QSAM Biosciences developing next-gen targeted radiopharmaceuticals for cancer

Synlogic advancing novel biotherapeutics based on synthetic biology

Iterion Therapeutics addressing multiple cancers with TBL1 inhibition

MindMed driving therapeutic potential of psychedelics for brain health disorders

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

General

More